Literature DB >> 20038749

Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.

Meena S Madhur1, Heinrich E Lob, Louise A McCann, Yoichiro Iwakura, Yelena Blinder, Tomasz J Guzik, David G Harrison.   

Abstract

We have shown previously that T cells are required for the full development of angiotensin II-induced hypertension. However, the specific subsets of T cells that are important in this process are unknown. T helper 17 cells represent a novel subset that produces the proinflammatory cytokine interleukin 17 (IL-17). We found that angiotensin II infusion increased IL-17 production from T cells and IL-17 protein in the aortic media. To determine the effect of IL-17 on blood pressure and vascular function, we studied IL-17(-/-) mice. The initial hypertensive response to angiotensin II infusion was similar in IL-17(-/-) and C57BL/6J mice. However, hypertension was not sustained in IL-17(-/-) mice, reaching levels 30-mm Hg lower than in wild-type mice by 4 weeks of angiotensin II infusion. Vessels from IL-17(-/-) mice displayed preserved vascular function, decreased superoxide production, and reduced T-cell infiltration in response to angiotensin II. Gene array analysis of cultured human aortic smooth muscle cells revealed that IL-17, in conjunction with tumor necrosis factor-alpha, modulated expression of >30 genes, including a number of inflammatory cytokines/chemokines. Examination of IL-17 in diabetic humans showed that serum levels of this cytokine were significantly increased in those with hypertension compared with normotensive subjects. We conclude that IL-17 is critical for the maintenance of angiotensin II-induced hypertension and vascular dysfunction and might be a therapeutic target for this widespread disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038749      PMCID: PMC2819301          DOI: 10.1161/HYPERTENSIONAHA.109.145094

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  42 in total

1.  Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats.

Authors:  Bernardo Rodríguez-Iturbe; Yasmir Quiroz; Mayerly Nava; Lizzette Bonet; Maribel Chávez; Jaime Herrera-Acosta; Richard J Johnson; Héctor A Pons
Journal:  Am J Physiol Renal Physiol       Date:  2002-02

2.  Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.

Authors:  Xin Zhang; Jianping Jin; Xueyan Peng; Vinod S Ramgolam; Silva Markovic-Plese
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

Authors:  Michael Platten; Sawsan Youssef; Eun Mi Hur; Peggy P Ho; May H Han; Tobias V Lanz; Lori K Phillips; Matthew J Goldstein; Roopa Bhat; Cedric S Raine; Raymond A Sobel; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

4.  Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge.

Authors:  Hiromasa Hamada; Maria de la Luz Garcia-Hernandez; Joyce B Reome; Sara K Misra; Tara M Strutt; Kai K McKinstry; Andrea M Cooper; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

5.  IL-17 induces monocyte migration in rheumatoid arthritis.

Authors:  Shiva Shahrara; Sarah R Pickens; Andrea Dorfleutner; Richard M Pope
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

6.  CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity.

Authors:  Joakim Huber; Florian W Kiefer; Maximilian Zeyda; Bernhard Ludvik; Gerd R Silberhumer; Gerhard Prager; Gerhard J Zlabinger; Thomas M Stulnig
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

7.  Association between the -2518G/A polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and hypertension in Tunisian patients.

Authors:  Riadh Jemaa; Samir Ben Ali; Amani Kallel; Souheil Omar; Moncef Feki; Monia Elasmi; Samah Haj-Taïeb; Haïfa Sanhaji; Naziha Kaabachi
Journal:  Clin Biochem       Date:  2008-10-18       Impact factor: 3.281

8.  Blood pressure-lowering effects of statins: who benefits?

Authors:  Leonelo E Bautista
Journal:  J Hypertens       Date:  2009-07       Impact factor: 4.844

9.  Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice.

Authors:  Zili Zhang; Wenwei Zhong; Doran Spencer; Hong Chen; Huiying Lu; Tatsushi Kawaguchi; James T Rosenbaum
Journal:  Cytokine       Date:  2009-02-28       Impact factor: 3.861

10.  Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.

Authors:  Raymond E Eid; Deepak A Rao; Jing Zhou; Sheng-fu L Lo; Hooman Ranjbaran; Amy Gallo; Seth I Sokol; Steven Pfau; Jordan S Pober; George Tellides
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

View more
  332 in total

1.  FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension.

Authors:  Valorie L Chiasson; Deepa Talreja; Kristina J Young; Piyali Chatterjee; Amy K Banes-Berceli; Brett M Mitchell
Journal:  Hypertension       Date:  2011-04-25       Impact factor: 10.190

2.  Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it?

Authors:  Sean P Didion
Journal:  Hypertension       Date:  2011-04-25       Impact factor: 10.190

Review 3.  Targeting NADPH oxidases in vascular pharmacology.

Authors:  Agata Schramm; Paweł Matusik; Grzegorz Osmenda; Tomasz J Guzik
Journal:  Vascul Pharmacol       Date:  2012-03-03       Impact factor: 5.773

4.  Identification of the primary outcomes that result from deficient spiral arterial modification in pregnant mice.

Authors:  B Anne Croy; Suzanne D Burke; Valerie F Barrette; Jianhong Zhang; Kota Hatta; Graeme N Smith; Juares Bianco; Aureo T Yamada; Michael A Adams
Journal:  Pregnancy Hypertens       Date:  2011-01-01       Impact factor: 2.899

Review 5.  Under pressure: the search for the essential mechanisms of hypertension.

Authors:  Thomas M Coffman
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 6.  The central nervous system and inflammation in hypertension.

Authors:  Paul J Marvar; Heinrich Lob; Antony Vinh; Faresa Zarreen; David G Harrison
Journal:  Curr Opin Pharmacol       Date:  2010-12-31       Impact factor: 5.547

Review 7.  The immune system in hypertension.

Authors:  Daniel W Trott; David G Harrison
Journal:  Adv Physiol Educ       Date:  2014-03       Impact factor: 2.288

Review 8.  The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension.

Authors:  David G Harrison
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

Review 9.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

Review 10.  Inflammation, immunity, and hypertensive end-organ damage.

Authors:  William G McMaster; Annet Kirabo; Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.